Cargando…

Hyperalgesia and Persistent Pain after Breast Cancer Surgery: A Prospective Randomized Controlled Trial with Perioperative COX-2 Inhibition

BACKGROUND: Persistent pain is a challenging clinical problem after breast cancer treatment. After surgery, inflammatory pain and nociceptive input from nerve injury induce central sensitization which may play a role in the genesis of persistent pain. Using quantitative sensory testing, we tested th...

Descripción completa

Detalles Bibliográficos
Autores principales: van Helmond, Noud, Steegers, Monique A., Filippini-de Moor, Gertie P., Vissers, Kris C., Wilder-Smith, Oliver H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5147830/
https://www.ncbi.nlm.nih.gov/pubmed/27935990
http://dx.doi.org/10.1371/journal.pone.0166601
_version_ 1782473740048662528
author van Helmond, Noud
Steegers, Monique A.
Filippini-de Moor, Gertie P.
Vissers, Kris C.
Wilder-Smith, Oliver H.
author_facet van Helmond, Noud
Steegers, Monique A.
Filippini-de Moor, Gertie P.
Vissers, Kris C.
Wilder-Smith, Oliver H.
author_sort van Helmond, Noud
collection PubMed
description BACKGROUND: Persistent pain is a challenging clinical problem after breast cancer treatment. After surgery, inflammatory pain and nociceptive input from nerve injury induce central sensitization which may play a role in the genesis of persistent pain. Using quantitative sensory testing, we tested the hypothesis that adding COX-2 inhibition to standard treatment reduces hyperalgesia after breast cancer surgery. A secondary hypothesis was that patients developing persistent pain would exhibit more postoperative hyperalgesia. METHODS: 138 women scheduled for lumpectomy/mastectomy under general anesthesia with paravertebral block were randomized to COX-2 inhibition (2x40mg parecoxib on day of surgery, thereafter 2x200mg celecoxib/day until day five) or placebo. Preoperatively and 1, 5, 15 days and 1, 3, 6, 12 months postoperatively, we determined electric and pressure pain tolerance thresholds in dermatomes C6/T4/L1 and a 100mm VAS score for pain. We calculated the sum of pain tolerance thresholds and analyzed change in these versus preoperatively using mixed models analysis with factor medication. To assess hyperalgesia in persistent pain patients we performed an additional analysis on patients reporting VAS>30 at 12 months. RESULTS: 48 COX-2 inhibition and 46 placebo patients were analyzed in a modified intention to treat analysis. Contrary to our primary hypothesis, change in the sum of tolerance thresholds in the COX-2 inhibition group was not different versus placebo. COX-2 inhibition had an effect on pain on movement at postoperative day 5 (p<0.01). Consistent with our secondary hypothesis, change in sum of pressure pain tolerance thresholds in 11 patients that developed persistent pain was negative versus patients without pain (p<0.01) from day 5 to 1 year postoperatively. CONCLUSIONS: Perioperative COX-2 inhibition has limited value in preventing sensitization and persistent pain after breast cancer surgery. Central sensitization may play a role in the genesis of persistent postsurgical pain.
format Online
Article
Text
id pubmed-5147830
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-51478302016-12-28 Hyperalgesia and Persistent Pain after Breast Cancer Surgery: A Prospective Randomized Controlled Trial with Perioperative COX-2 Inhibition van Helmond, Noud Steegers, Monique A. Filippini-de Moor, Gertie P. Vissers, Kris C. Wilder-Smith, Oliver H. PLoS One Research Article BACKGROUND: Persistent pain is a challenging clinical problem after breast cancer treatment. After surgery, inflammatory pain and nociceptive input from nerve injury induce central sensitization which may play a role in the genesis of persistent pain. Using quantitative sensory testing, we tested the hypothesis that adding COX-2 inhibition to standard treatment reduces hyperalgesia after breast cancer surgery. A secondary hypothesis was that patients developing persistent pain would exhibit more postoperative hyperalgesia. METHODS: 138 women scheduled for lumpectomy/mastectomy under general anesthesia with paravertebral block were randomized to COX-2 inhibition (2x40mg parecoxib on day of surgery, thereafter 2x200mg celecoxib/day until day five) or placebo. Preoperatively and 1, 5, 15 days and 1, 3, 6, 12 months postoperatively, we determined electric and pressure pain tolerance thresholds in dermatomes C6/T4/L1 and a 100mm VAS score for pain. We calculated the sum of pain tolerance thresholds and analyzed change in these versus preoperatively using mixed models analysis with factor medication. To assess hyperalgesia in persistent pain patients we performed an additional analysis on patients reporting VAS>30 at 12 months. RESULTS: 48 COX-2 inhibition and 46 placebo patients were analyzed in a modified intention to treat analysis. Contrary to our primary hypothesis, change in the sum of tolerance thresholds in the COX-2 inhibition group was not different versus placebo. COX-2 inhibition had an effect on pain on movement at postoperative day 5 (p<0.01). Consistent with our secondary hypothesis, change in sum of pressure pain tolerance thresholds in 11 patients that developed persistent pain was negative versus patients without pain (p<0.01) from day 5 to 1 year postoperatively. CONCLUSIONS: Perioperative COX-2 inhibition has limited value in preventing sensitization and persistent pain after breast cancer surgery. Central sensitization may play a role in the genesis of persistent postsurgical pain. Public Library of Science 2016-12-09 /pmc/articles/PMC5147830/ /pubmed/27935990 http://dx.doi.org/10.1371/journal.pone.0166601 Text en © 2016 van Helmond et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
van Helmond, Noud
Steegers, Monique A.
Filippini-de Moor, Gertie P.
Vissers, Kris C.
Wilder-Smith, Oliver H.
Hyperalgesia and Persistent Pain after Breast Cancer Surgery: A Prospective Randomized Controlled Trial with Perioperative COX-2 Inhibition
title Hyperalgesia and Persistent Pain after Breast Cancer Surgery: A Prospective Randomized Controlled Trial with Perioperative COX-2 Inhibition
title_full Hyperalgesia and Persistent Pain after Breast Cancer Surgery: A Prospective Randomized Controlled Trial with Perioperative COX-2 Inhibition
title_fullStr Hyperalgesia and Persistent Pain after Breast Cancer Surgery: A Prospective Randomized Controlled Trial with Perioperative COX-2 Inhibition
title_full_unstemmed Hyperalgesia and Persistent Pain after Breast Cancer Surgery: A Prospective Randomized Controlled Trial with Perioperative COX-2 Inhibition
title_short Hyperalgesia and Persistent Pain after Breast Cancer Surgery: A Prospective Randomized Controlled Trial with Perioperative COX-2 Inhibition
title_sort hyperalgesia and persistent pain after breast cancer surgery: a prospective randomized controlled trial with perioperative cox-2 inhibition
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5147830/
https://www.ncbi.nlm.nih.gov/pubmed/27935990
http://dx.doi.org/10.1371/journal.pone.0166601
work_keys_str_mv AT vanhelmondnoud hyperalgesiaandpersistentpainafterbreastcancersurgeryaprospectiverandomizedcontrolledtrialwithperioperativecox2inhibition
AT steegersmoniquea hyperalgesiaandpersistentpainafterbreastcancersurgeryaprospectiverandomizedcontrolledtrialwithperioperativecox2inhibition
AT filippinidemoorgertiep hyperalgesiaandpersistentpainafterbreastcancersurgeryaprospectiverandomizedcontrolledtrialwithperioperativecox2inhibition
AT visserskrisc hyperalgesiaandpersistentpainafterbreastcancersurgeryaprospectiverandomizedcontrolledtrialwithperioperativecox2inhibition
AT wildersmitholiverh hyperalgesiaandpersistentpainafterbreastcancersurgeryaprospectiverandomizedcontrolledtrialwithperioperativecox2inhibition